Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1899)	3/4/1999 11:45:00 AM
From: RCMac	Read Replies (1) \| Respond to of 10280

Peter, There was a nice article on bupropion (Zyban) in Tuesday's The New York Times: nytimes.com "The success rates of 40 percent to 60 percent that were achieved compare with 10 percent to 26 percent success rates among smokers who try to quit by using nicotine replacement alone." Also includes a nice tale about GLX turning down a grant application for studying bupropion as a smoking cessation drug - the researcher, Dr. Linda Ferry, got a small grant from the medical school where she teaches, ran a small clinical trial on her own at the VA hospital where she is on staff, and then went back to GLX, who was finally convinced - big pharma undeservedly saved from its own bumbling by good science and a bit of enterprise! --RCM